Vertex Pharmaceuticals Incorporated Establishes Early-Stage Huntington’s Disease Research Collaboration with CHDI, Inc.

SAN DIEGO--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated and CHDI Foundation, Inc. (CHDI) today announced a new collaboration aimed at developing assays for use in discovering novel compounds for the treatment of Huntington’s disease, a genetic neurodegenerative disease that affects approximately 30,000 people in the United States. CHDI is a non-profit foundation committed to accelerating the discovery and development of new drugs that delay the onset or slow the progression of Huntington’s disease.